Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

437 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-20

Study Completion Date

2017-04-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women

NCT07184827

Recurrent Urinary Tract Infections in Women

RECRUITING PHASE3

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

NCT06940622

Recurrent UTIs Recurrent Urinary Tract Infections Recurrent Urinary Tract Infections in Women +6 more

RECRUITING NA

Nutritional Supplementation for Recurrent Urinary Tract Infections in Women

NCT03597152

Recurrent Urinary Tract Infection

UNKNOWN NA

Nutraceutical Efficacy for rUTI

NCT03395288

Urinary Tract Infections

TERMINATED PHASE2/PHASE3

Patient Satisfaction and Long-term Safety of Intravesical Aminoglycoside Instillations in UTI Prevention

NCT05376670

Urinary Tract Infections Recurrent Urinary Tract Infection

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study represents the first time to use nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females. Urinary tract infection (UTI ) is the second most common bacterial infection, affecting women at a much higher frequency than men. There is a higher rate of recurrence of UTI, and a recurrent infection will follow 25-35% of initial UTI episodes within 3-6 months.

Intermittent or prolonged low dose antibiotic therapy has been used to treat and prevent recurrent UTI. Emerging of resistance to antimicrobial agents, enormous economic burden, and the side effects of antibiotics have led to the search for an alternative non-antibiotic prophylaxis of recurrent UTI. Nanotechnology structured water is a new type of drinking water that has been prepared using different types of energy fields and electromagnetic fields to produce this structured water, which has new and different characteristics from the ordinary water.

In the current study, the efficacy of nanotechnology structured water magnalife was compared with low-dose Trimethoprim and bottled drinking water for the prevention of recurrent UTI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Urinary Tract Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interventional (Group M)

The group of patients given nanotechnology structured water magnalife

Group Type EXPERIMENTAL

Nanotechnology Structured water Magnalife

Intervention Type DIETARY_SUPPLEMENT

Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules

Control (Group T)

The group of patients given Trimethoprim

Group Type ACTIVE_COMPARATOR

Trimethoprim

Intervention Type DRUG

Antibiotic

Placebo (Group O)

The group of patients given ordinary bottled drinking water

Group Type PLACEBO_COMPARATOR

Ordinary bottled drinking water

Intervention Type DIETARY_SUPPLEMENT

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nanotechnology Structured water Magnalife

Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules

Intervention Type DIETARY_SUPPLEMENT

Trimethoprim

Antibiotic

Intervention Type DRUG

Ordinary bottled drinking water

Placebo

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Magnalife 5200250040466 Proloprim

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 2 (two or more than two) UTI in the last 6 months
* ≥ 3 (three or more than three) UTI in the last 12 months

Exclusion Criteria

* immunotherapy
* radiotherapy
* malignancy
* steroids
* chronic infections
* chemotherapy
* immunosuppressive drugs
* anatomical abnormality of the urinary tract
* surgical operation the urinary tract

Minimum Eligible Age

24 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No